

Aye Aye Thike

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6757702/publications.pdf>

Version: 2024-02-01

67
papers

2,418
citations

257450

24
h-index

223800

46
g-index

67
all docs

67
docs citations

67
times ranked

3684
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelialâ€mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis. Journal of Clinical Pathology, 2022, 75, 316-323.	2.0	2
2	Artificial intelligence modelling in differentiating core biopsies of fibroadenoma from phyllodes tumor. Laboratory Investigation, 2022, 102, 245-252.	3.7	5
3	Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. Npj Breast Cancer, 2022, 8, 44.	5.2	4
4	Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 679-686.	2.8	10
5	Prognostic significance of phosphoglycerate dehydrogenase in breast cancer. Breast Cancer Research and Treatment, 2021, 186, 655-665.	2.5	9
6	Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing. Modern Pathology, 2021, 34, 1320-1332.	5.5	19
7	Medullary breast carcinoma: a pathologic review and immunohistochemical study using tissue microarray. Singapore Medical Journal, 2021, , .	0.6	2
8	Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. Histopathology, 2021, 79, 139-159.	2.9	9
9	Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice. Cancers, 2021, 13, 3875.	3.7	9
10	Epigenetic derepression converts PPARÎ³ into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discovery, 2021, 7, 265.	4.7	7
11	KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence. Breast Cancer Research and Treatment, 2021, , 1.	2.5	0
12	Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 825-833.	2.8	15
13	<i>MED12</i>, <i>TERT</i> and <i>RARA</i> in fibroepithelial tumours of the breast. Journal of Clinical Pathology, 2020, 73, 51-56.	2.0	25
14	Higher densities of tumourâ€infiltrating lymphocytes and CD4⁺ T cells predict recurrence and progression of ductal carcinoma <i>in situ</i> of the breast. Histopathology, 2020, 76, 852-864.	2.9	23
15	Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients. Breast Cancer Research, 2020, 22, 42.	5.0	20
16	Morphologic and genetic heterogeneity in breast fibroepithelial lesionsâ€a comprehensive mapping study. Modern Pathology, 2020, 33, 1732-1745.	5.5	13
17	Counting Mitoses With Digital Pathology in Breast Phyllodes Tumors. Archives of Pathology and Laboratory Medicine, 2020, 144, 1397-1400.	2.5	5
18	Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. Journal of Clinical Pathology, 2020, 73, 557-562.	2.0	53

#	ARTICLE	IF	CITATIONS
19	Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. Journal of Clinical Pathology, 2020, 73, 147-153.	2.0	7
20	PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. Journal of Clinical Pathology, 2020, 73, 463-469.	2.0	5
21	Genomic characterisation of breast fibroepithelial lesions in an international cohort. Journal of Pathology, 2019, 249, 447-460.	4.5	33
22	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 709-725.	2.8	14
23	Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. Breast Cancer Research and Treatment, 2019, 178, 295-305.	2.5	12
24	A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Medical Genomics, 2019, 12, 142.	1.5	20
25	Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Research and Treatment, 2019, 177, 17-27.	2.5	40
26	Behaviour and characteristics of low-grade ductal carcinoma <i>in situ</i> of the breast: literature review and single-centre retrospective series. Histopathology, 2019, 74, 970-987.	2.9	6
27	Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
28	Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. Clinical Cancer Research, 2019, 25, 2588-2600.	7.0	11
29	Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours. Breast Cancer Research and Treatment, 2019, 174, 365-373.	2.5	20
30	Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. Journal of Clinical Pathology, 2018, 71, 161-167.	2.0	23
31	Genetics and genomics of breast fibroadenomas. Journal of Clinical Pathology, 2018, 71, 381-387.	2.0	27
32	Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 615-621.	2.8	30
33	Molecular insights into paediatric breast fibroepithelial tumours. Histopathology, 2018, 73, 809-818.	2.9	11
34	Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 275-283.	2.8	7
35	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Frontiers in Immunology, 2018, 9, 1209.	4.8	114
36	Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer. Oncotarget, 2018, 9, 11619-11630.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 163, 21-35.	2.5	102
38	Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. Journal of Clinical Pathology, 2017, 70, 320-326.	2.0	36
39	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	12.4	165
40	Identifying progression predictors of breast ductal carcinoma in situ. Journal of Clinical Pathology, 2017, 70, 102-108.	2.0	29
41	A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology, 2017, 49, 786-789.	0.6	13
42	GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis. Oncotarget, 2017, 8, 115370-115383.	1.8	13
43	Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. Journal of Clinical Pathology, 2016, 69, 878-883.	2.0	9
44	MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression. Journal of Clinical Pathology, 2016, 69, 858-865.	2.0	26
45	Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2. Cancer Research, 2016, 76, 6278-6289.	0.9	62
46	Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors and outcomes. Breast Cancer Research and Treatment, 2016, 159, 229-244.	2.5	18
47	A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Research, 2016, 18, 31.	5.0	28
48	Breast carcinoma and phyllodes tumour: a case series. Journal of Clinical Pathology, 2016, 69, 364-369.	2.0	11
49	Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Research and Treatment, 2016, 156, 237-247.	2.5	122
50	Clinicopathological significance of <scp>ARID</scp> 1B in breast invasive ductal carcinoma. Histopathology, 2015, 67, 709-718.	2.9	15
51	Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. PLoS ONE, 2015, 10, e0134408.	2.5	15
52	False negative rate for intraoperative sentinel lymph node frozen section in patients with breast cancer: a retrospective analysis of patients in a single Asian institution. Journal of Clinical Pathology, 2015, 68, 536-540.	2.0	41
53	<i>MED12</i> is frequently mutated in breast phyllodes tumours: a study of 112 cases. Journal of Clinical Pathology, 2015, 68, 685-691.	2.0	62
54	Second harmonic generation microscopy is a novel technique for differential diagnosis of breast fibroepithelial lesions. Journal of Clinical Pathology, 2015, 68, 1033-1035.	2.0	13

#	ARTICLE	IF	CITATIONS
55	Paediatric fibroepithelial lesions revisited: pathological insights. Journal of Clinical Pathology, 2015, 68, 633-641.	2.0	26
56	CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. Journal of Clinical Pathology, 2015, 68, 200-205.	2.0	32
57	Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer. Experimental Biology and Medicine, 2015, 240, 846-853.	2.4	15
58	Genomic landscapes of breast fibroepithelial tumors. Nature Genetics, 2015, 47, 1341-1345.	21.4	167
59	CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Modern Pathology, 2015, 28, 352-358.	5.5	21
60	A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition. European Urology, 2015, 67, 17-20.	1.9	24
61	Assessment of suitability of the one step nucleic acid amplification (OSNA) assay as an intraoperative procedure for detection of metastasis in sentinel lymph nodes of breast cancer. Journal of Clinical Pathology, 2014, 67, 1032-1037.	2.0	5
62	Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Modern Pathology, 2014, 27, 352-360.	5.5	125
63	Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. Journal of Clinical Pathology, 2014, 67, 748-750.	2.0	23
64	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nature Genetics, 2014, 46, 877-880.	21.4	172
65	Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. Journal of Clinical Pathology, 2013, 66, 665-670.	2.0	25
66	Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers. American Journal of Surgical Pathology, 2010, 34, 956-964.	3.7	98
67	Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathology, 2010, 23, 123-133.	5.5	209